16 terminated. 16 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Terminated 16 |
| Phase 1 | 2 | Terminated 2 |
| Phase 3 | 2 | Terminated 2 |
Follow Gallbladder Neoplasms: new trials by email Literature Review of Gallbladder Neoplasms trials Research Report on Gallbladder Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer Irinotecan Liposome Injection, SG001, Fluorouracil - Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma | Phase 2 | Terminated | CSPC Ouyi Pharmaceutical Co., Ltd. | 17 | 2021-09-01 | 2024-07-11 |
| Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Seribantumab - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 2 | Terminated | Elevation Oncology | 54 | 2020-09-29 | 2025-04-03 |
| Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) CPI 613, Gemcitabine, Cisplatin - Biliary Tract Cancer | Phase 1 / Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 75 | 2020-06-23 | 2025-12-31 |
| Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC M7824, Placebo, Gemcitabine - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 / Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 309 | 2019-09-20 | 2023-11-14 |
| Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer Gemcitabine-Pazopanib - Cholangiocarcinoma, Gallbladder Carcinoma | Phase 2 | Terminated | Hellenic Cooperative Oncology Group | 29 | 2013-06-28 | 2018-11-07 |
| Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation Stereotactic Body Radiotherapy, Gemcitabine, Cisplatin - Cholangiocarcinoma, Hepatobiliary Neoplasm | Phase 2 | Terminated | Stanford University | 2 | 2011-01-01 | 2016-07-29 |
| Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers cediranib maleate, oxaliplatin, leucovorin calcium - Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 14 | 2010-10-01 | 2017-03-29 |
| Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer palonosetron hydrochloride, placebo - Anal Cancer, Carcinoma of the Appendix | Phase 2 | Terminated | Alliance for Clinical Trials in Oncology | 7 | 2009-09-01 | 2017-11-24 |
| A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer Gemcitabine, Oxaliplatin, Sorafenib - Cholangiocarcinoma, Biliary Tract Cancer | Phase 1 / Phase 2 | Terminated | University of Miami | 9 | 2009-08-01 | 2018-01-03 |
| Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers Cisplatin, Erlotinib, Gemcitabine - Hepatocellular Carcinoma, Cholangiocellular Carcinoma | Phase 2 | Terminated | New Mexico Cancer Research Alliance | 33 | 2007-08-01 | 2018-06-29 |
| Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery trastuzumab, laboratory biomarker analysis - Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder | Phase 2 | Terminated | National Cancer Institute (NCI) | 4 | 2007-05-01 | 2019-08-20 |
| Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo AMT2003 - Gastrointestinal Cancer, Prostate Cancer | Phase 2 / Phase 3 | Terminated | Auron Healthcare GmbH | 67 | 2006-05-01 | 2013-03-20 |
| Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder bortezomib - Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder | Phase 2 | Terminated | National Cancer Institute (NCI) | 20 | 2004-01-01 | 2017-07-02 |
| Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract carcinoembryonic antigen peptide 1-6D, incomplete Freund's adjuvant, sargramostim - Colorectal Cancer, Esophageal Cancer | Phase 2 | Terminated | The University of Texas Medical Branch, Galveston | 7 | 2002-07-01 | 2013-05-16 |
| BMS-247550 in Treating Patients With Liver or Gallbladder Cancer ixabepilone, laboratory biomarker analysis - Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 50 | 2001-08-01 | 2014-05-14 |
| Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer becatecarin - Extrahepatic Bile Duct Cancer, Gallbladder Cancer | Phase 2 | Terminated | Case Comprehensive Cancer Center | 72 | 1999-04-01 | 2010-06-11 |
Bile Duct Neoplasms (10) · Cholangiocarcinoma (8) · Carcinoma, Hepatocellular (6) · Liver Neoplasms (4) · Pancreatic Neoplasms (4) · Biliary Tract Neoplasms (3) · Colonic Neoplasms (3) · Colorectal Neoplasms (3) · Esophageal Neoplasms (3) · Stomach Neoplasms (3) · Gastrointestinal Neoplasms (2) · Lung Neoplasms (2) · Prostatic Neoplasms (2) · Rectal Neoplasms (2)
Biliary Tract Diseases (16) · Digestive System Diseases (16) · Digestive System Neoplasms (16) · Gallbladder Diseases (16) · Neoplasms by Site (16) · Neoplasms (15) · Adenocarcinoma (13) · Biliary Tract Neoplasms (13) · Carcinoma (13) · Neoplasms by Histologic Type (13) · Neoplasms, Glandular and Epithelial (13) · Bile Duct Diseases (10) · Liver Diseases (8) · Gastrointestinal Diseases (5) · Colonic Diseases (4)
Gemcitabine (6) · Cisplatin (4) · Fluorouracil (3) · Leucovorin (2) · Oxaliplatin (2) · Bortezomib (1) · Capecitabine (1) · Carboplatin (1) · Erlotinib Hydrochloride (1) · Liver Transplantation (1) · Palonosetron (1) · Radiosurgery (1) · Sorafenib (1) · Trastuzumab (1) · becatecarin (1)
National Cancer Institute (NCI) (4) · Alliance for Clinical Trials in Oncology (1) · Auron Healthcare GmbH (1) · CSPC Ouyi Pharmaceutical Co., Ltd. (1) · Case Comprehensive Cancer Center (1) · EMD Serono Research & Development Institute, Inc. (1) · Elevation Oncology (1) · Hellenic Cooperative Oncology Group (1) · New Mexico Cancer Research Alliance (1) · Stanford University (1) · The University of Texas Medical Branch, Galveston (1) · University of Miami (1) · University of Michigan Rogel Cancer Center (1)
United States (13) · Australia (2) · China (2) · Germany (2) · South Korea (2) · Argentina (1) · Bosnia and Herzegovina (1) · Brazil (1) · Canada (1) · Chile (1) · France (1) · Greece (1) · Italy (1) · Japan (1) · Poland (1)
Afshin Dowlati, MD (1) · Ahmed Kaseb (1) · Ari D Baron, MD (1) · Daniel T Chang (1) · Hedy Kindler (1) · Joachim Drevs, PD Dr. Med (1) · Joseph Sgouros, MD (1) · Michele Yvette Halyard, MD (1) · Peter Hosein, MD (1) · Robert P. Whitehead, MD (1) · Smitha Krishnamurthi (1) · Steven Cohen (1) · Vaibhav Sahai, MBBS, MS (1) · Xiangdong Cheng (1)
PMID 19399502, PMID 24512954, PMID 32461347, PMID 38875119, PMID 41428976
2019 (1), N01CM00070 (1), N01CM62201 (1), N01CM62202 (1), P30CA014599 (1), P30CA043703 (1), U01CA062502 (1), U01CA063200 (1)